India’s pharmaceutical exports continued to demonstrate strong resilience in FY26, surpassing ₹2.86 lakh crore. Despite facing global headwinds such as pricing pressures, regulatory complexities, and geopolitical uncertainties, the sector maintained steady growth and reinforced its global standing. India has consistently positioned itself as a reliable supplier of affordable, high-quality medicines worldwide. This strength stems from its robust manufacturing infrastructure and diversified export base.
Key export segments include generic formulations, bulk drugs (APIs), vaccines, and biosimilars. Meanwhile, major markets such as the United States, Europe, Africa, and several emerging economies continue to drive demand, ensuring balanced and sustained export performance.
Competitive Edge Drives Sustained Growth
The pharmaceutical sector benefits from a strong competitive advantage in cost-efficient production and stringent regulatory compliance. As a result, Indian companies continue to meet global quality standards while maintaining affordability. Rising global demand for high-quality generics and the industry’s expansion into complex therapies have significantly contributed to export growth. At the same time, improvements in domestic pharmaceutical infrastructure have further strengthened production capabilities.
Policy Support and Industry Initiatives Boost Momentum
Government initiatives have played a crucial role in accelerating growth. Notably, the Production Linked Incentive (PLI) scheme for pharmaceuticals and bulk drugs has encouraged domestic manufacturing and reduced reliance on imports. In addition, Indian pharmaceutical companies are actively investing in research and development, securing regulatory approvals, and diversifying product portfolios. These efforts are helping the industry tap into high-value and regulated markets more effectively.
Rising Investments in Advanced Therapies
The sector is also witnessing increased investments in biotechnology, biosimilars, and specialty drugs. Consequently, India is steadily moving up the value chain and strengthening its global competitiveness in advanced pharmaceutical segments. India’s pharmaceutical industry is well-positioned to sustain its growth trajectory. Innovation, regulatory alignment, and expanding global healthcare demand will continue to act as key growth drivers. Moreover, a strategic focus on emerging markets, value-added products, and supply chain resilience will further enhance export potential.
A Key Pillar of Global Healthcare
As reported by ibef.org, India’s strong export performance in FY26 underscores its critical role in the global pharmaceutical landscape. By consistently delivering affordable and high-quality medicines, the country continues to expand access to healthcare worldwide while reinforcing its position as a trusted global pharma hub.
